[Clinical sequelae of tissue angiotensin converting enzyme inhibition: practicability of use in ischemic heart disease].
Harmonic combination of efficacy and safety allowed angiotensin converting enzyme inhibitors (ACEI) to conquer popularity among physicians in the treatment of hypertension, heart failure, myocardial infarction, diabetic and non-diabetic nephropathy. This multiprofile application is determined by their action not only on systemic but also on tissue renin-angiotensin systems which augmented activity plays important role in genesis of various pathological states. One of novel and most promising directions of use of ACEI especially of those with inherent high tissue specificity and vascular selectivity (quinapril, perindopril, ramipril, trandolapril) is the treatment of atherosclerosis. Antiatherosclerotic effects of ACEI were studied in a variety of clinical trials with assessment of their effect on long term outcome. These trials demonstrated positive action of ACEI on the clinical course of cardiovascular and cerebrovascular diseases. Expediency of prescription of ACEI to patients with atherosclerosis of coronary vessels and other vascular beds irrespective of the presence of hypertension and heart failure becomes now obvious.
Karpov
Iu A
IuA
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy*
D000806:Angiotensin-Converting Enzyme Inhibitors